One of the first studies which analysed the prognosis for infracentimetric tumours assessed a population of 242 patients with lymph node negative breast cancer, of which 19% were HER-2+ tumours, versus 83% with HER-2 negative (HER-2-). Here, ERBB2 is linked to neoplasm.